Meridian Bioscience Acquires Exalenz Bioscience - FinSMEs
#Acquisition
Exalenz Bioscience Acquired for $49M
#Acquisition
Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience;Adds State-Of-The-Art Urea Breath Test Diagnostics Platform
#Acquisition
Meridian Bioscience to Buy Exalenz Bioscience for $49M
#Acquisition
Exalenz Bioscience seeks buyer
#Investment #Customers
Exalenz Bioscience Receives Approval for Commercial Marketing in China for Its BreathID® Hp Lab System
#Customers
Exalenz to Present Positive Clinical Data for the Breath ID® 13C-Methacetin Breath Test System at the Liver Meeting® 2018
#Partners
Exalenz Bioscience raises NIS 15.6m in Tel Aviv
#Public Trading
Exalenz Bioscience's Non-Invasive BreathID® Test to be Evaluated in Two Bristol-Myers Squibb Phase 2b Clinical Trials in Adult Patients with NASH
#Partners
Exalenz Announces Confidential Submission of Draft Registration Statement for Initial Public Offering
#Public Trading
Exalenz Bioscience Receives FDA Clearance for Pediatric Helicobacter Pylori Testing
#Customers
Exalenz Bioscience Announces Positive Clinical Trial Results For the Diagnosis of Clinically Significant Portal Hypertension in NASH Patients MarketScreener
#Customers #Expand
Exalenz Bioscience Launches Automated BreathID® Hp Lab Urea Breath Testing System For Helicobacter pylori Detection
#Expand
Exalenz Bioscience plans Nasdaq IPO
#Public Trading
Exalenz Bioscience jumps on LabCorp deal
#Customers #Partners
Exalenz Bioscience Receives FDA Marketing Clearance For Its Laboratory System In The United States
#Customers
Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID® to Monitor Patients with Cirrhosis Associated with NASH
#Partners
Exalenz Bioscience raises NIS 23.5m in TASE offering
#Investment #Expand
Exalenz Bioscience starts liver diagnostics trial
#Investment #Expand
Exalenz Granted US Patent for Liver Application of Company's BreathID Platform Technology
undefined
Exalenz Bioscience Announces the Global Market Launch of the New BreathID® Hp for Detection and Management of H. pylori
#Customers #Partners
Arkin's AccelMed invests in diagnostics co Peer Medical - Globes
#Investment